Resectable Hepatocellular Carcinoma clinical trials

Explore recruiting resectable hepatocellular carcinoma clinical trials.

Recruiting resectable hepatocellular carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Resectable Hepatocellular Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC)

Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Study of the benefit of lenvatinib treatment in waiting list of liver transplantation after TACE failure in patients with hepatocellular carcinoma (HCC) : Ta-Len-Tra

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on objective response rate in the treatment of unresectable hepatocellular carcinoma patients (DEMAND)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCEULLULAR CARCINOMA (MORPHEUS-NEO HCC)

Austria, Spain, Germany, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Resectable Hepatocellular Carcinoma trials by city

Resectable Hepatocellular Carcinoma in Toronto Resectable Hepatocellular Carcinoma in Vancouver Resectable Hepatocellular Carcinoma in Montreal Resectable Hepatocellular Carcinoma in Calgary Resectable Hepatocellular Carcinoma in Edmonton Resectable Hepatocellular Carcinoma in Ottawa Resectable Hepatocellular Carcinoma in Winnipeg Resectable Hepatocellular Carcinoma in Quebec City Resectable Hepatocellular Carcinoma in Hamilton Resectable Hepatocellular Carcinoma in Kitchener Resectable Hepatocellular Carcinoma in London Resectable Hepatocellular Carcinoma in Halifax Resectable Hepatocellular Carcinoma in New York Resectable Hepatocellular Carcinoma in Los Angeles Resectable Hepatocellular Carcinoma in Chicago Resectable Hepatocellular Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease